Compare DexCom, Inc. (DXCM) vs TKO Group Holdings Inc (TKO) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

TKO trades at $182.895, down 0.9% on the day, with a bearish technical signal despite strong analyst support. The company shows solid revenue growth from $4.74B in 2025 to $5.1B projected for 2026, though net margins remain modest at 4.47%. Recent developments include successful international events and an $800 million share repurchase, while technical indicators show support at $180 and resistance at $188.

The stock presents a mixed outlook with strong Wall Street bullishness (89% buy ratings) and a $228.40 price target offering 25% upside potential. However, elevated P/E ratio of 69.03 and recent earnings misses create valuation concerns. Key risks include execution challenges in monetizing live events and competitive pressures in sports entertainment.